ATE427117T1 - Verwendung nativer peptide und deren optimierter derivate zur impfung - Google Patents

Verwendung nativer peptide und deren optimierter derivate zur impfung

Info

Publication number
ATE427117T1
ATE427117T1 AT06743108T AT06743108T ATE427117T1 AT E427117 T1 ATE427117 T1 AT E427117T1 AT 06743108 T AT06743108 T AT 06743108T AT 06743108 T AT06743108 T AT 06743108T AT E427117 T1 ATE427117 T1 AT E427117T1
Authority
AT
Austria
Prior art keywords
vaccination
optimized
native
peptides
native peptides
Prior art date
Application number
AT06743108T
Other languages
English (en)
Inventor
Kostantinos Kosmatopoulos
Original Assignee
Vaxon Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxon Biotech filed Critical Vaxon Biotech
Application granted granted Critical
Publication of ATE427117T1 publication Critical patent/ATE427117T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06743108T 2005-05-09 2006-05-09 Verwendung nativer peptide und deren optimierter derivate zur impfung ATE427117T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05290984 2005-05-09

Publications (1)

Publication Number Publication Date
ATE427117T1 true ATE427117T1 (de) 2009-04-15

Family

ID=37396914

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06743108T ATE427117T1 (de) 2005-05-09 2006-05-09 Verwendung nativer peptide und deren optimierter derivate zur impfung

Country Status (13)

Country Link
US (2) US8663645B2 (de)
EP (1) EP1879612B1 (de)
JP (1) JP5435938B2 (de)
CN (1) CN101171032B (de)
AT (1) ATE427117T1 (de)
BR (1) BRPI0608768B1 (de)
CA (1) CA2606871C (de)
DE (1) DE602006006046D1 (de)
DK (1) DK1879612T3 (de)
ES (1) ES2323895T3 (de)
PL (1) PL1879612T3 (de)
PT (1) PT1879612E (de)
WO (1) WO2006120038A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010010A1 (en) 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
CN102153658A (zh) * 2011-01-19 2011-08-17 上海科医联创生物科技有限公司 肿瘤抗原、dc肿瘤疫苗及其制备方法
WO2013036201A1 (en) * 2011-09-06 2013-03-14 Agency For Science, Technology And Research Polypeptide vaccine
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
EP3400954A1 (de) * 2017-05-09 2018-11-14 Vaxon Biotech Impfstoff zur abzielung auf ein kryptisches tert-epitop zur behandlung von lungenkrebs in einem hla-a*0201-positiven patienten, der nie oder weniger geraucht hat
EP3400959A1 (de) * 2017-05-09 2018-11-14 Vaxon Biotech Verwendung eines impfstoffes zur abzielung auf ein kryptisches tert-epitop zur behandlung von krebs in einem hla-a*0201-positiven patienten mit einem nichtimmunogenen tumorexprimierenden tert
WO2018217982A1 (en) * 2017-05-26 2018-11-29 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
FR3097123A1 (fr) * 2019-06-11 2020-12-18 Vaxon Biotech Combinaison de marqueurs pour prédire la réponse à Vx-001
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527449A (ja) * 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
EP1434859A2 (de) * 2001-07-25 2004-07-07 New York University Verwendung von glycosylceramiden als adjuvantien für vakzine gegen infektionen und krebs
FR2837837B1 (fr) * 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
FR2838742B1 (fr) 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2

Also Published As

Publication number Publication date
CN101171032A (zh) 2008-04-30
JP2008540483A (ja) 2008-11-20
EP1879612A2 (de) 2008-01-23
DE602006006046D1 (de) 2009-05-14
BRPI0608768A2 (pt) 2010-01-26
CN101171032B (zh) 2012-02-29
WO2006120038A2 (en) 2006-11-16
BRPI0608768B1 (pt) 2019-08-20
EP1879612B1 (de) 2009-04-01
CA2606871A1 (en) 2006-11-16
PT1879612E (pt) 2009-06-30
JP5435938B2 (ja) 2014-03-05
CA2606871C (en) 2014-06-03
US8663645B2 (en) 2014-03-04
ES2323895T3 (es) 2009-07-27
WO2006120038A3 (en) 2007-07-19
DK1879612T3 (da) 2009-07-20
US20080254051A1 (en) 2008-10-16
US20140178421A1 (en) 2014-06-26
PL1879612T3 (pl) 2009-08-31

Similar Documents

Publication Publication Date Title
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
ATE427117T1 (de) Verwendung nativer peptide und deren optimierter derivate zur impfung
WO2007039192A3 (en) Compositions and methods for treating tumors presenting survivin antigens
BRPI0817299A8 (pt) vacinas e componentes de vacina para inibição de células microbianas
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
CY1121132T1 (el) ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
MX359680B (es) Vacunas peptídicas para cánceres que expresan antígenos hig2 asociados con tumores.
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MY171854A (en) Wt1 antigen peptide conjugate vaccine
CO6470802A2 (es) Péptido auxiliar del antígeno del cáncer
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
ECSP099341A (es) Nuevos anticuerpos antiproliferativos
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
ATE404225T1 (de) Radiofluorierte peptide
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
CY1113726T1 (el) Χρηση της πασιρεοτιδης για την αντιμετωπιση της ενδογενους υπερινσουλιναιμικης υπογλυκαιμιας
WO2020022898A3 (en) Off-the-shelf cancer vaccines
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
NZ596501A (en) Casb7439 constructs
WO2010056144A3 (en) Foxp3+ natural kiler t-cells and the treatment of immune related diseases
NZ594198A (en) Neil3 peptides and vaccines including the same
MX380003B (es) Péptidos topk y vacunas que incluyen los mismos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1879612

Country of ref document: EP